Table 4a Mean and total cost of CAR-T clinical pathway by phase: IRCCS AOU BO Orsola
From: Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Clinical pathway phases | # of patients | Mean cost per patient | % | Total cost | % |
|---|---|---|---|---|---|
Analysis of patient eligibility | 59 | €54 | 9% | €3,164 | 14% |
Assessment of patient eligibility | 52 | €858 | €44,623 | ||
Consent form management, Drug choice, Communication to the relevant pharmaceutical companies | 52 | €284 | €14,778 | ||
Apheresis planning | 52 | €2,499 | €129,972 | ||
Apheresis / Therapy Request Procedure | 44 | €650 | €28,621 | ||
Pre-hospitalization / Lymphocyte engineering process | 36 | €4,516 | €162,570 | ||
Inpatient episode: Lymphocyte reception / Hospitalization / Bridge therapy / Infusion / Monitoring / Toxicity management | 29 | €67,033 | 71% | €1,943,960 | 71% |
Discharge | 27 | €226 | 20% | €6,101 | 15% |
Follow-up (+ 30 days) | 24 | €11,623 | €278,952 | ||
Follow up (+ 120 days) | 21 | €6,955 | €146,053 | ||
Total (living patients after 120 days of follow-up) | 21 | €94,699 | 100% | €2,758,793 | 100% |
Total (patients reported as eligible) | 59 | €46,759 |